1. Clinical & Scientific Overview
Micronised Progesterone (Oral / Vaginal Softgel) & Isoxsuprine Hydrochloride (TIP-MED-000458, Reference Code [12.18]) is classified under
Obstetric & Gynaecological Medicines as a Natural Bioidentical Corpus Luteum Progesterone & Beta-Adrenergic Uterine Vasodilator/Tocolytic (Schedule H).
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Registered Medical Practitioner).
Representative Indian Formulations (for identification only): Micronised Progesterone: Susten (Sun — 100, 200, 300, 400 mg Softgel, 8% Vaginal Gel, IM), Naturogest (Zydus), Hald, Lupigest (Lupin). | Strengths: Micronised Progesterone Softgel Capsules (suitable for Oral, Vaginal, or Rectal insertion!): 100 mg, 200 mg, 300 mg, 400 mg; SR Tablets: 200 mg, 300 mg; Vaginal Gel: 8% (90 mg). Isoxsuprine Tablets: 10 mg IR, 40 mg SR; Injection: 10 mg/2 mL
Standard hospital formulary strengths
3. Mechanism of Action & Pharmacodynamics
Established pharmacological class action (Natural Bioidentical Corpus Luteum Progesterone & Beta-Adrenergic Uterine Vasodilator/Tocolytic (Schedule H)): targets primary receptor, enzyme, ion-channel, or cellular pathway to achieve therapeutic efficacy in Micronised Progesterone: **Luteal Phase Support** in ART/IVF cycles, **Prevention of Preterm Birth** in women with a short cervix (<25 mm on mid-trimester ultrasound) or history of spontaneous preterm birth (**200 mg Vaginal Softgel HS from 16–24 weeks to 36 weeks!**), threatened/recurrent miscarriage, secondary amenor.
4. Therapeutic Indications & Evidence-Supported Uses
- Micronised Progesterone: **Luteal Phase Support** in ART/IVF cycles, **Prevention of Preterm Birth** in women with a short cervix (<25 mm on mid-trimester ultrasound) or history of spontaneous preterm birth (**200 mg Vaginal Softgel HS from 16–24 weeks to 36 weeks!**), threatened/recurrent miscarriage, secondary amenor
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Micronised Progesterone: **Vaginal Insertion (Luteal Support / Threatened Miscarriage / Short Cervix)**: **200–400 mg inserted high into the vagina ONCE or TWICE DAILY** (Vaginal route delivers a 10-fold higher uterine endometrial concentration via the 'first-uterine-pass effect' while completely avoiding hepatic 5-alp. (Duration: Threatened miscarriage: Up to 12–16 weeks gestation; Short cervix preterm prophylaxis: Up to 36 weeks gestation)
Administration & Meal Timing: Oral (PO), Parenteral (IV / IM / SC as specified), Topical / Cutaneous | Food & Meal Timing: CRITICAL ROUTE & TIMING RULE FOR MICRONISED PROGESTERONE (SUSTEN / NATUROGEST): The exact same 200 mg softgel capsule can be swallowed OR inserted vaginally! (1) **If prescribed ORALLY**: MUST be take. | Best Time of Day: Oral Progesterone: Strictly at Bedtime (HS). Vaginal Progesterone: Bedtime (OD) or Morning & Bedtime (BD)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Renal: Safe (Vaginal route preferred). Hepatic: Avoid oral route in hepatic impairment (use vaginal route if required)
Renal: Safe (Vaginal route preferred). Hepatic: Avoid oral route in hepatic impairment (use vaginal route if required)
Renal: Safe (Vaginal route preferred). Hepatic: Avoid oral route in hepatic impairment (use vaginal route if required)
7. Contraindications, Precautions & High-Risk Warnings
- Micronised Progesterone CONTRAINDICATED in active thromboembolism (DVT/PE), severe hepatic dysfunction, breast/genital malignancy, missed/incomplete abortion, and **Peanut / Soya Allergy (check brand excipient — some softgel capsules use arachis/peanut oil or soy lecithin suspension!)**
Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
8. Adverse Effects Profile
- Micronised Progesterone: **Oral route**: Marked drowsiness, dizziness/vertigo (15–25% within 1–3h of swallowing!), headache, breast tenderness
- Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CYP3A4 inducers (Rifampicin, Carbamazepine, Phenytoin) accelerate Progesterone clearance
- Vaginal antifungal creams (Clotrimazole/Miconazole pessaries) should not be inserted simultaneously with Vaginal Progesterone softgels (reduces progesterone release from the lipid base!)
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.
Pharmacist Patient Counselling Points:
- THREE VITAL OBSTETRIC COUNTER RULES FOR SUSTEN / NATUROGEST: (1) **Always clarify the route**: the box says 'For Oral / Vaginal / Rectal Use' — for pregnancy support, doctors usually want the softgel **inserted deep into the vagina** (which goes straight to the womb with zero dizziness), whereas if swallowed by mouth it must be taken **on
Storage, Stability & Dispensing Safeguards: Store in original moisture-protected packaging below 25°C–30°C (or 2°C–8°C cold chain if parenteral/biological vial specified in strengths: Micronised Progesterone Softgel Capsules (suitable for Oral, Vaginal, or Rectal insertion!): 100 mg, 200 mg, 300 mg, 400 mg; SR Tablets: 200 mg, 300 mg; Vaginal Gel: 8% (90 mg). Isoxsuprine Tablets: 10 mg IR, 40 mg SR; Injection: 10 mg/2 mL). Missed-Dose Rule: Insert/take as soon as remembered
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.3] Losartan Potassium — Angiotensin II Receptor Blocker (ARB; selective AT1 antagonist)
- [3.4] Olmesartan Medoxomil — Angiotensin II Receptor Blocker (ARB) (Ester Prodrug)
- [3.1] Amlodipine (as Amlodipine Besylate) — Dihydropyridine Calcium Channel Blocker (CCB); Arterial Vasodilat
- [3.2] Telmisartan — Angiotensin II Receptor Blocker (ARB) with Partial PPAR-gamma Ago